Salient Pharma ApS
CVR 36900709 · Private limited company (ApS) · Active · Low risk
Salient Pharma ApS is a Private limited company (ApS), founded on , based in Glostrup. The company is registered in the industry engroshandel med medicinalvarer og sygeplejeartikler. Our model estimates a bankruptcy risk of 0.2% over the next 12 months, which is 0.2 times the average for Danish companies. 11 annual reports have been published, of which 4 more than six months after the end of the financial year. The latest annual report (31 Dec 2025) shows equity of DKK -1.3m and a net result of DKK -218k. CEO: Ulrik Spork.
Bankruptcy risk for Salient Pharma ApS
0.2 × the average (1.41%) · higher risk than 49% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 36900709
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (11 years)
- Address
- c/o Biofarma Logistik, Naverland 22
2600 Glostrup - Municipality
- Albertslund
- Industry
- Engroshandel med medicinalvarer og sygeplejeartikler (464610)
Bankruptcies in the industry: Engroshandel med andre maskiner og andet udstyr - Share capital
- DKK 420k
- Auditor
- GE REVISION & RÅDGIVNING, REGISTRERET REVISIONSANPARTSSELSKAB
- Audit opted out
- Yes
Warning signs
| Annual reports filed late | 4 of 11 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -3,018.5% |
| Current ratio | 3% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 0 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 21 |
| Going-concern uncertainty | Yes |
Financials and key figures
| Financial year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Gross profit | DKK -130k | DKK -124k | DKK -233k |
| Net profit | DKK -218k | DKK -202k | DKK -305k |
| Equity | DKK -1.3m | DKK -1.1m | DKK -1.2m |
| Total assets | DKK 45k | DKK 19k | DKK 21k |
| Cash | DKK 10k | DKK 18k | – |
| Short-term debt | DKK 1.4m | DKK 1.1m | – |
| Avg. employees | 0 | 0 | – |
Latest annual report: Reporting class B · auditor's statement: Andre erklæringer uden sikkerhed · GE REVISION & RÅDGIVNING, REGISTRERET REVISIONSANPARTSSELSKAB.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 176 | ||
| 1 Jan 2024 – 31 Dec 2024 | 174 | ||
| 1 Jan 2023 – 31 Dec 2023 | 180 | ||
| 1 Jan 2022 – 31 Dec 2022 | 188 | Late | |
| 1 Jan 2021 – 31 Dec 2021 | 192 | Late | |
| 1 Jan 2020 – 31 Dec 2020 | 202 | Late | |
| 1 Jan 2019 – 31 Dec 2019 | 272 | Late | |
| 1 Jan 2018 – 31 Dec 2018 | 158 | ||
| 1 Jan 2017 – 31 Dec 2017 | 159 | ||
| 1 Jan 2016 – 31 Dec 2016 | 154 | ||
| 21 May 2015 – 31 Dec 2015 | 161 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Ulrik Spork | Current | |
| Board | Ulrik Spork | Current | |
| Board | Søren Wang Petersen | Current | |
| Board | Helle Bøwadt | Current | |
| Board | Søren Johannes Kjær Henningsen | ||
| Owner (33%) | HB-MEDICAL HOLDING ApS | Current | |
| Owner (15%) | CAND.PHARM. POVL M. ASSENS FOND | Current | |
| Owner (25%) | SPORCON LIFESCIENCE ADVISORS ApS | Current | |
| Owner (100%) | SPORCON LIFESCIENCE ADVISORS ApS | ||
| Owner (50%) | HB-MEDICAL HOLDING ApS | ||
| Owner (25%) | SPORCON LIFESCIENCE ADVISORS ApS | ||
| Owner (15%) | Kjær Henningsen Holding ApS | ||
| Owner (33%) | HB-MEDICAL HOLDING ApS | ||
| Owner (10%) | Kjær Henningsen Holding ApS | ||
| Owner (15%) | CAND.PHARM. POVL M. ASSENS FOND | ||
| Owner (10%) | CAND.PHARM. POVL M. ASSENS FOND | ||
| Owner (5%) | Kjær Henningsen Holding ApS | ||
| Owner (5%) | Kjær Henningsen Holding ApS | ||
| Auditor | DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB | ||
| Founder | SPORCON LIFESCIENCE ADVISORS ApS | Current |
The CEOs' other companies
Ulrik Spork – 26 other companies, of which 3 bankrupt
- PRONOSCO A/S Bankrupt 11 Dec 2001
- RETINALYZE A/S Bankrupt 19 Aug 2003
- StatuManu ICP ApS Bankrupt 22 Jan 2025
- AZANTA DANMARK A/S Active
- Cerebriu A/S Active
- Colosal Medical ApS Fusioneret
- DIANOVA A/S Active
- Dansk Vækstkapital II Komplementar ApS Active
- InnoCon Medical ApS Active
- LEUKOTECH ApS Opløst
- MGS Design & Development A/S Active
- MS RESEARCH A/S Opløst
- MedTrace Pharma A/S Active
- NEURESCUE ApS Active
- NEW XELLIA GROUP A/S Active
- NOAPAB HOLDINGS A/S Opløst
- OrfoNeuro ApS Active
- PRECISENSE A/S Opløst
- Practio ApS Opløst
- ROS Therapeutics ApS Opløst
- Reapplix A/S Active
- Roto Health ApS Active
- SPORK HOLDING ApS Active
- Sovitae ApS Active
- VEGGERBY SPORT OG KULTUR A/S Active
- XELLIA HOLDCO A/S Active
Address history (2 moves)
| c/o Biofarma Logistik, Naverland 22, 2600 Glostrup | |
| c/o Ulrik Spork, Naverland 22, 2600 Glostrup | |
| c/o Ulrik Spork, Taarbæk Strandvej 108A, 2930 Klampenborg |
Former names
| Salient Pharma ApS | – now |
| Salient Pharma IVS | – |
| ZeroTaste IVS | – |
Other companies at the same address
- AHS ApS Bankrupt
- Green-TJEK ApS Bankrupt
- HOB WATCH ApS Bankrupt
- SCANKON ApS Bankrupt
- SKANDINAVISK KONVOLUT TRYK ApS Bankrupt
- AMO DENMARK ApS Active
- BIOFARMA LOGISTIK A/S Active
- Bannebjerg Holding ApS Active
- Biofarma Holding A/S Active
- EFB ELEKTRONIK NORDIC A/S Active
- EJECO A/S Fusioneret
- FRISBÆK HOLDING APS Active
- FRISBÆK ApS Active
- K. E. Hansen Holding ApS Active
- KEH Gruppen ApS Active
- NAVICO DANMARK A/S Opløst
- PHARMAVEST ApS Active
- POBRA HOLDING ApS Fusioneret
- S-COM DENMARK ApS Opløst
- Tinvej 13 ApS Active
- hameln pharma ApS Active
Similar companies in Albertslund
- BIOFARMA LOGISTIK A/S Glostrup
- Pharma Supply ApS Albertslund
- hameln pharma ApS Glostrup
- CONMED DENMARK ApS Glostrup
- PROTESEKOMPAGNIET A/S Albertslund
- SELMAT ApS Albertslund
- KEBOMED A/S Glostrup
- Direct Healthcare Group Danmark A/S Albertslund
- AMO DENMARK ApS Glostrup
- PHARMAVEST ApS Glostrup
- Afpro Filters ApS Albertslund
- Selskabet af 1. juli 2017 ApS Albertslund
Questions and answers about Salient Pharma ApS
Has Salient Pharma ApS gone bankrupt?
No, Salient Pharma ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Salient Pharma ApS?
Our model estimates a bankruptcy risk of 0.2% over the next 12 months (low risk), which is 0.2 times the average for Danish companies.
Who is the CEO of Salient Pharma ApS?
Ulrik Spork is the CEO of Salient Pharma ApS.
Who is the auditor of Salient Pharma ApS?
Salient Pharma ApS most recently used GE REVISION & RÅDGIVNING, REGISTRERET REVISIONSANPARTSSELSKAB.
When was Salient Pharma ApS founded?
Salient Pharma ApS was founded on 21 May 2015.
What is the equity of Salient Pharma ApS?
Equity was DKK -1.3m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.